Haider, Malik Salman
Ahmad, Taufiq
Groll, Jürgen
Scherf-Clavel, Oliver
Kroiss, Matthias
Luxenhofer, Robert http://orcid.org/0000-0001-5567-7404
Funding for this research was provided by:
Higher Education Commission, Pakistan
Deutsche Forschungsgemeinschaft (314061271)
Julius-Maximilians-Universität Würzburg
Article History
Accepted: 24 June 2021
First Online: 21 July 2021
Change Date: 10 November 2021
Change Type: Update
Change Details: The original version is updated due to request on integrate of funding note.
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. Malik Salman Haider received a PhD scholarship from the Higher Education Commission of Pakistan and German Academic Exchange Services (HEC-DAAD Pakistan). This study was further supported by the German Research Foundation [Deutsche Forschungsgemeinschaft (DFG)], project number 314061271—CRC/TRR 205, to Matthias Kroiss.
: Matthias Kroiss declares that he has received travel support from HRA Pharma, the manufacturer of Lysodren<sup>®</sup> in Europe. Robert Luxenhofer is listed as an inventor of patents pertinent to some materials discussed in this contribution and co-founder of DelAqua Pharmaceutical Inc., which is intent on clinical development of poly(2-oxazoline)-based drug formulations.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: MSH had the conceptual idea for the article. The literature search was performed by MSH and TA. The first draft of the manuscript was written by MSH, and all authors commented on subsequent versions of manuscript and provided a critical revision for important intellectual content. All authors read and approved the final manuscript.